slenyto
rad neurim pharmaceuticals eec sarl - melatonin - sleep initiation and maintenance disorders; autistic disorder - psycholeptics - slenyto indiciran za liječenje nesanice kod djece i adolescenata u dobi od 2 do 18 s poremećajem autističnog spektra (asd) i / ili smith-magenis sindrom, gdje spavati higijenske mjere su dovoljne.
moxi 400 mg/1 tableta film tableta
zada pharmaceuticals d.o.o. - moksifloksacin - film tableta - 400 mg/1 tableta - 1 film tableta sadrži 400 mg moksifloksacina (u obliku moksifloksacinhidrohlorida)
moxi 400 mg/1 tableta film tableta
zada pharmaceuticals d.o.o. - moksifloksacin - film tableta - 400 mg/1 tableta - 1 film tableta sadrži 400 mg moksifloksacin (u obliku moksifloksacinhidrohlorida)
zinforo
pfizer ireland pharmaceuticals - fosamil цефтаролин - community-acquired infections; skin diseases, infectious; pneumonia - antibakterijski lijekovi za sistemsku primjenu, - zinforo is indicated for the treatment of the following infections in neonates, infants, children, adolescents and adults: , complicated skin and soft tissue infections (cssti), community-acquired pneumonia (cap) , consideration should be given to official guidance on the appropriate use of antibacterial agents.
efox 250 mg filmom obložene tablete
mibe pharmaceuticals d.o.o., zavrtnica 17, zagreb, hrvatska - cefuroksimaksetil - filmom obložena tableta - 250 mg - urbroj: jedna filmom obložena tableta sadrži 250 mg cefuroksima u obliku cefuroksimaksetila
efox 500 mg filmom obložene tablete
mibe pharmaceuticals d.o.o., zavrtnica 17, zagreb, hrvatska - cefuroksimaksetil - filmom obložena tableta - 500 mg - urbroj: jedna filmom obložena tableta sadrži 500 mg cefuroksima u obliku cefuroksimaksetila
enspryng
roche registration gmbh - satralizumab - neuromyelitis optica - imunosupresivi - satralizumab (enspryng) is indicated as a monotherapy or in combination with immunosuppressive therapy (ist) for the treatment of neuromyelitis optica spectrum disorders (nmosd) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 igg (aqp4-igg) seropositive.
ultomiris
alexion europe sas - ravulizumab - hemoglobinuria, paroxysmal - selektivni imunosupresivi - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.
uplizna
horizon therapeutics ireland dac - inebilizumab - neuromyelitis optica - imunosupresivi - uplizna is indicated as monotherapy for the treatment of adult patients with neuromyelitis optica spectrum disorders (nmosd) who are anti-aquaporin 4 immunoglobulin g (aqp4-igg) seropositive (see section 5.
moxifloksacin lek 400 mg/1 tableta filmom obložena tableta
novartis ba d.o.o. - moksifloksacin - filmom obložena tableta - 400 mg/1 tableta - 1 filmom obložena tableta sadrži: 400 mg moksifloksacina u obliku hidrohlorida